Managing smoking cessation
- PMID: 17615224
- PMCID: PMC1910650
- DOI: 10.1136/bmj.39252.591806.47
Managing smoking cessation
Conflict of interest statement
Competing interests: PA receives a personal income from the UK National Health Service and the University of Birmingham. He has received research funds from the NHS, and various research charities and has received hospitality from various pharmaceutical companies, including those making products for smoking cessation. He has received free drugs for distribution to trial participants from King Pharmaceuticals and Novartis Consumer Health Care and has received consultancy income to him and his institution from Xenova Biotechnology and Pfizer for advice on smoking cessation. RW undertakes research and consultancy for, and has received hospitality and travel funds from, manufacturers of smoking cessation drugs and has a share of a patent for a novel nicotine delivery device.
Figures
Comment in
-
Managing smoking cessation: Article skips over weaknesses of nicotine replacement.BMJ. 2007 Jul 21;335(7611):112. doi: 10.1136/bmj.39275.964514.BE. BMJ. 2007. PMID: 17641310 Free PMC article. No abstract available.
References
-
- West R. Smoking and smoking cessation in England: 2006. www.smokinginengland.info/Ref/paper4.pdf
-
- Taylor T, Lader D, Bryant A, Keyse L, Joloza MT. Smoking-related behaviour and attitudes, 2005 London: Office for National Statistics, 2006. www.statistics.gov.uk/downloads/theme_health/Smoking2005.pdf
-
- West R. Defining and assessing nicotine dependence in humans. In: Corrigall WA, ed. Understanding nicotine and tobacco addiction London: Wiley, 2006:36-63.
-
- Balfour DJK. The neurobiology of tobacco dependence: A preclinical perspective on the role of the dopamine projections to the nucleus. Nicotine Tob Res 2004;6:899-912. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical